Holen Sie sich die Stockscreener-App
197.60
2.52%
-5.11
Handel nachbörslich:
198.00
0.40
+0.20%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EFX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$202.71
Offen:
$199.87
24-Stunden-Volumen:
2.83M
Relative Volume:
1.66
Marktkapitalisierung:
$23.79B
Einnahmen:
$5.94B
Nettoeinkommen (Verlust:
$661.30M
KGV:
37.45
EPS:
5.2762
Netto-Cashflow:
$999.40M
1W Leistung:
+9.15%
1M Leistung:
-12.94%
6M Leistung:
-17.54%
1J Leistung:
-21.90%
1-Tages-Spanne:
$192.41
$201.00
1-Wochen-Bereich:
$180.72
$203.88
52-Wochen-Spanne:
$166.02
$281.03
Equifax Inc Stock (EFX) Company Profile
Firmenname
Equifax Inc
Sektor
Branche
Telefon
(404) 885-8000
Adresse
1550 PEACHTREE ST NW, ATLANTA, GA
Compare EFX vs VRSK, BAH, FCN, HURN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EFX
Equifax Inc
|
197.60 | 24.41B | 5.94B | 661.30M | 999.40M | 5.2762 |
|
VRSK
Verisk Analytics Inc
|
173.77 | 23.62B | 3.03B | 914.60M | 1.12B | 6.5505 |
|
BAH
Booz Allen Hamilton Holding Corp
|
79.79 | 10.85B | 11.78B | 870.25M | 844.17M | 6.70 |
|
FCN
Fti Consulting Inc
|
156.81 | 5.35B | 3.73B | 312.01M | 434.78M | 8.70 |
|
HURN
Huron Consulting Group Inc
|
131.11 | 2.51B | 1.47B | 85.47M | 106.27M | 4.60 |
Equifax Inc Stock (EFX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2025-10-01 | Eingeleitet | Seaport Research Partners | Neutral |
| 2025-07-10 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-06-23 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-04-10 | Fortgesetzt | BofA Securities | Buy |
| 2025-04-04 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-03-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-14 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2025-02-11 | Herabstufung | Argus | Buy → Hold |
| 2024-12-16 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2024-12-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-01 | Eingeleitet | UBS | Buy |
| 2024-09-19 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2024-08-13 | Eingeleitet | Wells Fargo | Overweight |
| 2024-07-09 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-01-11 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-08 | Hochstufung | BofA Securities | Underperform → Buy |
| 2024-01-04 | Bestätigt | Needham | Buy |
| 2023-12-19 | Eingeleitet | Oppenheimer | Outperform |
| 2023-12-18 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Buy |
| 2023-07-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-01-06 | Eingeleitet | Exane BNP Paribas | Underperform |
| 2022-11-15 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2022-10-21 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-10-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-15 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-07-13 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-21 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-30 | Eingeleitet | Deutsche Bank | Hold |
| 2022-03-11 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-31 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-01-27 | Hochstufung | Truist | Hold → Buy |
| 2022-01-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2021-10-22 | Hochstufung | Argus | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-07-23 | Bestätigt | Goldman | Neutral |
| 2021-07-08 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-12-15 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-12-11 | Hochstufung | Stifel | Hold → Buy |
| 2020-12-08 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-10-07 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-10-06 | Eingeleitet | Needham | Buy |
| 2020-07-10 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2020-06-09 | Herabstufung | SunTrust | Buy → Hold |
| 2020-05-15 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-04-06 | Herabstufung | Argus | Buy → Hold |
| 2020-03-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-02 | Hochstufung | Exane BNP Paribas | Underperform → Outperform |
| 2020-01-17 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Eingeleitet | Jefferies | Buy |
| 2019-03-15 | Eingeleitet | Exane BNP Paribas | Underperform |
| 2019-02-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2018-12-07 | Fortgesetzt | Credit Suisse | Outperform |
| 2018-10-26 | Bestätigt | Barclays | Equal Weight |
| 2018-10-23 | Fortgesetzt | BofA/Merrill | Underperform |
| 2018-04-10 | Eingeleitet | BofA/Merrill | Underperform |
| 2017-12-14 | Herabstufung | Barclays | Overweight → Equal Weight |
Alle ansehen
Equifax Inc Aktie (EFX) Neueste Nachrichten
Equifax (EFX) Valuation Check After Earnings Beat, 2026 Outlook, Buybacks And New Growth Initiatives - simplywall.st
Here's Why You Should Hold Equifax Stock in Your Portfolio Now - Yahoo Finance
Equifax's Q4 Earnings Call: Our Top 5 Analyst Questions - Finviz
Madison Asset Management LLC Increases Stock Position in Equifax, Inc. $EFX - MarketBeat
Equifax, Inc. $EFX Shares Bought by Oppenheimer Asset Management Inc. - MarketBeat
Why (EFX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
19,038 Shares in Equifax, Inc. $EFX Purchased by Katamaran Capital LLP - MarketBeat
Equifax’s Q4 Earnings Call: Our Top 5 Analyst Questions - The Globe and Mail
EFX Price Target Lowered to $208 by Goldman Sachs | EFX Stock Ne - GuruFocus
Equifax (EFX) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Needham & Company LLC Lifts Earnings Estimates for Equifax - MarketBeat
Equifax accused of price gouging Medicaid programs - WSAW
Gen Digital Links AI Agent Security With Equifax Powered Consumer Protection - Yahoo Finance
Equifax Inc. (EFX) Unveils Credit Card Origination and Employment Insight Solutions - Finviz
Envestnet Asset Management Inc. Raises Stake in Equifax, Inc. $EFX - MarketBeat
Equifax’s AI Push, Cloud Shift And Buybacks Might Change The Case For Investing In EFX - simplywall.st
Equifax providing a new six-year credit-monitoring service to victims of 2017 data breach - WGAL
Gen Digital, Equifax Partner To Offer Tools For Managing Finances And Online Security - Crowdfund Insider
Equifax Fell 6% Last Week. Here’s Where the Stock Could Head in 2026 - TIKR.com
Goldman Sachs Adjusts Equifax Price Target to $208 From $235, Maintains Neutral Rating - marketscreener.com
Equifax Announces Earnings Release Date and Conference Call for Fourth Quarter 2025 Results - Eastern Progress
Research Alert: CFRA Lowers Rating On Shares Of Equifax Inc. To Hold From Buy - 富途牛牛
Senators accuse Equifax of price gouging - KVUE
JPMorgan Chase & Co. Has Lowered Expectations for Equifax (NYSE:EFX) Stock Price - MarketBeat
JP Morgan Lowers Price Target for EFX, Maintains Overweight Rati - GuruFocus
EFX: Stifel Maintains Buy Rating, Lowers Price Target to $235 | - GuruFocus
Senators investigate Equifax's role in Medicaid verification - NonStop Local KHQ
Royal Bank Of Canada Issues Pessimistic Forecast for Equifax (NYSE:EFX) Stock Price - MarketBeat
Equifax (EFX) Valuation Reassessed After Recent Share Price Pullback - Yahoo Finance
Equifax (EFX) Maintains Equal-Weight, Price Target Lowered by Ba - GuruFocus
EFX: RBC Capital Maintains Rating and Lowers Price Target | EFX Stock News - GuruFocus
Senators Accuse Equifax of ‘Price-Gouging’ Medicaid Programs - The New York Times
Getting a new Bilt or Apple Card soon? How to maximize your credit score during a transition - CNBC
EFX Analyst Update: Morgan Stanley Lowers Price Target to $244 | - GuruFocus
EFX: Wells Fargo Lowers Price Target but Maintains Overweight Ra - GuruFocus
Wells Fargo & Company Has Lowered Expectations for Equifax (NYSE:EFX) Stock Price - MarketBeat
Wells Fargo Adjusts Price Target on Equifax to $240 From $265, Maintains Overweight Rating - marketscreener.com
Baird Adjusts Price Target on Equifax to $250 From $289, Maintains Outperform Rating - marketscreener.com
These Analysts Cut Their Forecasts On Equifax After Q4 Earnings - Benzinga
Barclays Adjusts Price Target on Equifax to $215 From $240, Maintains Equalweight Rating - marketscreener.com
JPMorgan Adjusts Price Target on Equifax to $230 From $260, Maintains Overweight Rating - marketscreener.com
Equifax (EFX) Faces Target Price Adjustment Amidst Maintained Bu - GuruFocus
RBC Cuts Price Target on Equifax to $222 From $250, Keeps Outperform Rating - marketscreener.com
Needham & Company LLC Lowers Equifax (NYSE:EFX) Price Target to $265.00 - MarketBeat
Equifax Inc. (NYSE: EFX) Q4 2025 earnings call transcript - MSN
Equifax Inc. (NYSE:EFX) Q4 2025 Earnings Call Transcript - Insider Monkey
Senators Demand Answers on Equifax Plan to 'Profiteer' Off GOP Medicaid Work Requirements - Common Dreams
Breaking Down Equifax: 5 Analysts Share Their Views - Benzinga
Equifax: Resilient Data Moat and FICO-Driven Upside Undervalued, Supporting Buy Rating - TipRanks
Morgan Stanley Lowers Price Target on Equifax to $244 From $269, Keeps Overweight Rating - marketscreener.com
Equifax (NYSE:EFX) Sets New 1-Year LowWhat's Next? - MarketBeat
Finanzdaten der Equifax Inc-Aktie (EFX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.54%
11.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):